San Francisco 00:35:19
Cologne 09:35:19
Cape Town 10:35:19
Dubai 12:35:19
Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T,
Morisaki T, Furue M, Akashi K, Naito S. Department of Urology, Graduate
School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Objectives: To evaluate the safety and efficacy of dendritic cell (DC)
therapy in combination with interferon-alpha (IFN-alpha) in patients with
advanced renal cell carcinoma. Methods: Seven patients, with progressive
disease following IFN-alpha and interleukin (IL)-2 treatment, were treated
with monocyte-derived DC (Mo-DC) and IFN-alpha between February 2004 and
September 2006. They received Mo-DC once a week for 5 weeks and then every 2
weeks either intradermally or intratumorally. IFN-alpha (5-6 million U) was
subcutaneously administered three times a week. Tumor size was evaluated by
computed tomography scans before and after the 5th and 10th DC vaccination. A
delayed-type hypersensitivity test was performed after the 4th and 5th DC
administration for immunological monitoring. Results: Five patients had
stable disease while the remaining two patients had progressive disease
following 4 months of vaccination. In six patients the time to progression
was prolonged in comparison with the previous cytokine treatment. Six
patients showed delayed-type hypersensitivity after the 4th or 5th
immunization. Three patients developed high fever following DC immunization.
Treatment was associated with transient flu-like symptoms. Conclusions: Our
data indicate that DC therapy combined with IFN-alpha is safe and has the
potential for prolonging the time to progression in patients with advanced
renal cell carcinoma.
PMID: 18564205 [PubMed - as supplied by publisher]
Webdesign: © barrierefreies-webdesign.net Axel Jung | Diplom Designer | Köln
